FDA Approves Adjuvant Pembrolizumab for Non-Small Cell Lung Cancer Treatment
The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with
Everything about lung cancer is here.
The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with
The US Food and Drug Administration (FDA) has granted accelerated approval for Mirati Therapeutics’ Krazati (adagrasib) for treatment of mutated
Lung cancer patients now have another treatment option. For those tumors carrying HER2 mutations, can now be treated with trastuzumab
U.S. Food and Drug Administration (FDA) has approved the FoundationOne CDx as a companion diagnostic to guide treatment selection for
The FDA has approved nivolumab plus platinum-doublet chemotherapy for patients with non-small cell lung cancer in the neoadjuvant setting. Nivolumab
European Commission (EC) has granted marketing authorization for Lorviqua as monotherapy for treatment of patients with anaplastic lymphoma kinase (ALK)